Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis

Clinical Infectious Diseases

Volumn 33, Issue 4, 2001, Pages 562-569

  Graham, C S ^a   Baden, L R ^b   Yu, E ^e   Mrus, J M ^d   Carnie, J ^f   Heeren, T ^c   Koziel, M J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f Department of Human Services ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; DISEASE DURATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL;

HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER DISEASES; RISK;

EID: 0035882187     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/321909     Document Type: Article

References (38)

1. Hepatitis C: Global prevalence
2. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
3. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
4. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients
5. Natural history of liver fibrosis progression in patients with chronic hepatitis C
6. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
7. Natural history of hepatitis C: Its impact on clinical management
8. 45-Year follow-up of hepatitis C virus infection in healthy young adults
9. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection
10. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
11. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study
12. The natural history of chronic hepatitis C in haemophiliacs
13. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV
14. The progression of HCV-associated liver disease in a cohort of haemophilic patients
15. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: A comparison between immunocompetent and immunocompromised patients
16. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C
17. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
18. Increasing mortality due to endstage liver disease in patients with human immunodeficiency virus infection
19. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users
20. Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV
21. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
22. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
23. Meta-analysis in clinical trials
24. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
25. Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection
26. Cause of death in hemophilia A patients in the United States from 1968 to 1979
27. Haemophiliacs with factor VIII inhibitors in Finland: Prevalence, incidence and outcome
28. Mortality before and after HIV infection in the complete UK population of haemophiliacs
29. Chronic liver disease in central Harlem: The role of alcohol and viral hepatitis
30. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
31. Anti-protease inhibitor therapy decreases the liver fibrosis progression rate in HIV-HCV coinfected patients
32. Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy
33. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy
34. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
35. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
36. The role of immune responses in the pathogenesis of hepatitis C virus infection